Approval · Notice of Compliance 25219 · 2021
TEVA-ABIRATERONE: Notice of Compliance 25219
Issued February 16, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25219
- Date
- February 16, 2021
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph
- Canadian reference product
- ZYTIGA (Janssen Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-ABIRATERONE | Not yet assigned | — |
Medicinal ingredients
- ABIRATERONE ACETATE 500 MG per TAB